NAD+, or nicotinamide adenine dinucleotide, is essential for various biological processes within a dog's body. It helps convert food into energy by facilitating metabolic reactions, particularly in the mitochondria, the energy-producing structures in cells. As dogs age, levels of NAD+ naturally decline, which can lead to decreased energy production, impaired cellular repair mechanisms, and a greater susceptibility to age-related diseases. This decline is part of the broader aging process and can affect both physical health and overall vitality in our canine companions. Research in geroscience suggests that boosting NAD+ levels may help combat some of the negative effects of aging. By enhancing cellular repair and metabolic function, higher NAD+ levels could potentially contribute to improved longevity and quality of life for dogs. This is particularly relevant in the context of developing longevity-focused therapies, where maintaining optimal NAD+ levels might support healthier aging in our furry friends, helping them to remain active and vibrant well into their senior years.
GLOSSARY
NAD+
NAD+ is a crucial coenzyme found in all living cells that plays a key role in cellular metabolism and energy production.
Why it matters
Understanding NAD+ helps dog owners appreciate the importance of cellular health in promoting their pet's longevity and well-being.
Be first when the pill ships near you
Free, forever, and ad-free.
Keep exploring
mythMyth vs fact: Microchips cause tumors in dogs.newsPre-launch dossier: what we know about the canine longevity pill in 2026blogThe evidence on omega-3 fish oil for senior dogs (it's better than you think)glossaryGlossary: TelomereblogThe pet insurance industry's quiet pivot to longevity coveragebreedCane Corso longevity briefglossaryGlossary: LifespancountryPill watch: RomaniamythMyth vs fact: Feeding dogs bigger meals at night helps them sleep better tmythMyth vs fact: Big dogs simply can't live long.mythMyth vs fact: Brushing a dog's teeth is only for cosmetic purposes and doenewsGeroscience consortium adds three more breeds to dose-finding study